Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibited powerful in vitro potency against the SARS-CoV-2 Omicron variant
| | | |

Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibited powerful in vitro potency against the SARS-CoV-2 Omicron variant

On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…

Sanofi and Parkinson’s Foundation collaborated to advance availability of free genetic testing and counseling for people with Parkinson’s disease
| | |

Sanofi and Parkinson’s Foundation collaborated to advance availability of free genetic testing and counseling for people with Parkinson’s disease

On Jun. 1, 2021, Sanofi announced that Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus…

Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
| |

Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection

On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…